Este sitio web fue traducido automáticamente. Para obtener más información, por favor haz clic aquí.
Updated

Nearly 700,000 people live with primary brain and central nervous system tumors in the United States, according to the American Brain Tumor Association. This year, experts estimate an added 25,000 primary malignant brain tumors will be diagnosed, while some 17,000 patients will die from the disease. There may be hope, however, in the work of an interdisciplinary pair: a 3D-printing expert and a tumor biologist.

Supported by a 67,000 ($98,000) grant from the Brain Tumor Charity, a team led by Dr. Will Shu and Dr. Nicholas Leslie of Heriot-Watt University's Institute of Biological Chemistry, Biophysics and Bioengineering will 3D print brain tumor stem and cancerous cells using a unique technique, reports The National. The scientists then hope to study the printed tumors and experiment on them with various drug treatments.

Related: A group of Harvard and MIT students have created a lung cancer breathalyzer system

"We have developed a novel 3D-printing technique to print brain tumor cells for the first time, cells that continue to grow rapidly, more closely mimicking the growth of these aggressive tumors in real life," Dr. Leslie told The National. "Our goal is that this should provide a new way of testing drugs to treat brain tumors, leading to new treatments and speeding up the process by which new drugs become available to patients."

Laboratory-grown cancer cells don't usually behave as they do in the body since it's too difficult to recreate the tumor's biological environment. This means previous attempts to grow and test them haven't offered scientists the valuable insight they were hoping for. By recreating the environment within our body, Dr. Shu and Dr. Leslie hope their technique will better resemble the cancer cells' growth in patients' brains, and thus allow for more beneficial experiments.

"The prognosis for newly diagnosed brain tumor patients is currently very poor and improvements have been very limited, in large part due to the failure in clinical trials of many new drugs," Dr. Shu told The National. "We hope our research will help develop a model that closely matches … the response of individuals' brain tumors to drugs, allowing more effective treatment to be carried out for patients."